New biotechnology holding company ElevateBio launches in Cambridge, US

pharmaceutical-business-review | May 15, 2019

new biotechnology holding company in the form of ElevateBio has been launched in Cambridge, Massachusetts with an objective to develop a portfolio of cell and gene therapy companies. ElevateBio is backed by $150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in the biotechnology holding company include EcoR1 Capital, Redmile Group, and Samsara BioCapital. MPM Capital co-founder Ansbert Gadicke said: “At MPM, we are thrilled to have incubated ElevateBio, a company that is creating a novel environment to accelerate the development of cell and gene therapies for patients and deliver significant value to investors. “The track records of the ElevateBio leadership team in building iconic companies and creating value are unmatched, and we look forward to working with them as they execute on a new model in the field of cell and gene therapies.”

Spotlight

The genome of the cockroach was recently sequenced, and scientists have gained some insight into why they are so tough. They can survive in an incredible array of environments, they are great at reproducing, they can get over severe wounds, and as it turns out, they are also evolving. Some roaches now know to avoid certain insecticides.

Spotlight

The genome of the cockroach was recently sequenced, and scientists have gained some insight into why they are so tough. They can survive in an incredible array of environments, they are great at reproducing, they can get over severe wounds, and as it turns out, they are also evolving. Some roaches now know to avoid certain insecticides.

Related News

MEDICAL

Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology was originally developed in the laboratory of Institute Professor Robert Langer at MIT to facilitate rapid, local administration of therapeutics to treat serious diseases. “Therapeutic translation of oligos has been hampered by delivery and bioavailability issues with a complicated landscape for chemical-based formulations. This further demonstrates our capability to deliver RNAs and siRNAs to knockdown relevant gene targets without the need for any formulation.” Dr. Carl Schoellhammer, corresponding author, and Suono Bio co-founder In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. ABOUT SUONO BIO Suono Bio was founded by Robert Langer and Giovanni Traverso, a gastroenterologist and biomedical engineer from the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. The company is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic.

Read More

CELL AND GENE THERAPY

Discovery Life Sciences Launches GMP Compliant Discovery Leukopaks™ to Accelerate Research and Development of Cell and Gene Therapies

Discovery Life Sciences | October 28, 2020

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel therapies requires fast and reliable access to high quality, well-characterized human cellular raw materials. Discovery's reputation for speed and quality will be a boon to researchers around the globe. Discovery's launch of GMP-compliant Discovery Leukopaks and derivatives adds to Discovery's existing RUO (research-use-only) fresh and cryopreserved leukopaks and isolated immune cell populations. Discovery's next-generation short and long read sequencing and flow cytometry services can be incorporated to provide highly characterized, reliable human cellular materials for research, development, and GMP manufacturing.

Read More

MEDICAL

Lilly, Vir Biotechnology and GSK Collaborates to Evaluate a Combination of two COVID-19 Therapies in Low-risk Patients

Lilly | January 28, 2021

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first occasion when that monoclonal antibodies from discrete organizations will be united to explore expected results. Bamlanivimab is a neutralizing antibody coordinated against the spike protein of SARS-CoV-2 designed to obstruct viral connection and entry into human cells, in this manner killing the infection. Bamlanivimab emerged out of the collaboration among Lilly and AbCellera to make antibody therapies for the avoidance and treatment of COVID-19. Bamlanivimab is approved for emergency use for the treatment of mild to direct COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. "Bamlanivimab is a potent antibody – with data from multiple Phase 2 and 3 clinical trials, which have demonstrated robust evidence for both treating and preventing COVID-19," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "With a virus like SARS-CoV-2, it's expected that variants could emerge that require new therapeutic options, which is why Lilly is studying bamlanivimab together with other neutralizing antibodies, including etesevimab. Adding VIR-7831 to our study is an important part of our commitment to develop therapies to treat current and future strains of COVID-19 until vaccines are widely available and utilized."

Read More